Chief Medical Officer Simon Amy Reports Disposal of Common Shares of Beam Therapeutics Inc

Beam Therapeutics Acquires Early-Stage Life Sciences Firm

BRIEF-Beam Therapeutics Buys Early-Stage Life Sciences Company

Beam Therapeutics Inc - Potential Additional Payments up to $89 Mln - SEC Filing

Beam Therapeutics Inc - Buys Early-Stage Life Sciences Company - SEC Filing

Beam Therapeutics Inc. Issues 403,128 Shares as Upfront Payment and Announces Potential Additional Milestone Shares Worth Up to $89 Million in Acquisition Deal

Beam Therapeutics (BEAM) Gets a Buy from Wedbush

Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (MRUS) and Beam Therapeutics (BEAM)

Beam Therapeutics’ BEAM-101: Promising Advancements in Sickle Cell Disease Treatment with Strong Phase 1/2 Trial Results

Beam Therapeutics Announces Promising New Data from BEACON Phase 1/2 Trial of BEAM-101 for Sickle Cell Disease at EHA 2025 Congress

Beam Therapeutics Inc - Enrollment Complete in Beacon Trial, 30 Patients Expected by Mid-2025

Beam Therapeutics Announces New Data From Beacon Phase 1/2 Clinical Trial of Beam-101 Supporting Differentiated Profile in Sickle Cell Disease (Scd) at European Hematology Association (Eha) 2025 Congress

Beam Therapeutics Confirms Key Decisions at Annual Meeting

Bernstein Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture Global

嗡嗡声--美国股票走势-Hims & Hers Health、Microstrategy、联邦快递

Roadzen’s DrivebuddyAI Awarded Patent for Real-Time Driver Drowsiness Detection — Crosses 1.8 Billion Kilometers of Real-World AI Driving Data